Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-Lung 6 trial
Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-Lung 6 trial
复制标题
DOI：
10.2147/ott.s160358
复制
发表时间：
2018-01-01
影响因子：
4
通讯作者：
Zhou, Caicun
中科院分区：
文献类型：
--
作者：
Wu, Yi-Long;Xu, Chong-Rui;Zhou, Caicun
非小细胞肺癌（NSCLC）是中国癌症死亡的主要原因。四种表皮生长因子受体（EGFR）靶向酪氨酸激酶抑制剂——阿法替尼、厄洛替尼、伊可替尼和吉非替尼——可用于中国非小细胞肺癌的一线治疗；然而，很少有数据来指导治疗选择。III期LUX-Lung 6试验比较了阿法替尼与铂基化疗在东南亚EGFR突变阳性晚期NSCLC患者一线治疗中的应用。这项事后分析评估了LUX-Lung 6在中国患者中的发现。材料和方法：先前未经治疗的EGFR突变阳性IIIB/IV期肺腺癌患者随机分为2组：1组接受阿法替尼治疗
Introduction: Non-small-cell lung cancer (NSCLC) is the leading cause of cancer death in China. Four epidermal growth factor receptor (EGFR)-targeted tyrosine kinase inhibitors - afatinib, erlotinib, icotinib, and gefitinib - are available for first-line treatment of NSCLC in China; however, there are few data to guide treatment choice. The Phase III LUX-Lung 6 trial compared afatinib with platinum-based chemotherapy for first-line treatment of patients from Southeast Asia with EGFR mutation-positive advanced NSCLC. This post hoc analysis assessed the findings from LUX-Lung 6 in Chinese patients.Materials and methods: Previously untreated patients with EGFR mutation-positive stage IIIB/IV lung adenocarcinoma were randomized 2: 1 to receive afatinib or